Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018The Hemophilia Therapeutics Market is Forecast to Show Significant Growth Until 2018
By: Rajesh Gunnam $10.9 billion by 2018 at a compound annual growth rate (CAGR) of 6.0%. The hemophilia therapeutics market is classified as either hemophilia A (including patients with inhibitors) or hemophilia B (including patients with inhibitors). The hemophilia A therapeutics market is expected to grow at a CAGR of 6.1% from $6.0 billion in 2010 to $9.6 billion in 2018. The hemophilia B therapeutics market is expected to grow at a CAGR of 5.7% from $868m in 2010 to $1,353m in 2018. The current market is served by Recombinate NovoSeven, Advate, BeneFIX, XYNTHA, Kogenate FS, FEIBA VH, Mononine and Monoclate-P, among others. The hemophilia therapeutics market currently offers coagulation factor enhancers and coagulation factor substitutes. These drugs are able to cater to the market demand moderately in terms of efficacy, offering symptomatic relief but not a complete cure for the disease. Hemophilia patients require frequent coagulation factor replacement infusions throughout their treatment, which has been a major concern leading to poor patient compliance. Therefore, there is a significant clinical unmet need for effective disease modifying therapies that target the underlying pathophysiology of hemophilia. The major limitation of the currently marketed products is their short duration of action and the need for frequent dosing, which remains a significant clinical unmet need. A new entrant that can offer longer duration of action, less frequent dosing and improved efficacy and safety will have significant market potential. In the late stage of development, there are various novel formulations of existing marketed treatment options such as PEGylated version, long-acting and fast-acting recombinant molecules. The protein engineering techniques, such as Fc Fusion, PEGylation, PSAylation and HESylation are being adapted by the companies to differentiate their products from existing ones. The presence of novel formulations with different half-life properties and ease of administration will increase the patient compliance by reducing the dose of factor concentrates in near future. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ Increasing awareness among patients with hemophilia is leading to the demand for prophylactic treatment. Prophylactic therapy is an early preventive strategy which helps to reduce the frequency of bleeding episodes. Treating bleeding with preventive therapy has shown reduced joint damage and is widely believed to reduce the risk of life threatening hemorrhages and intra-cranial bleeding. Consequently, preventative therapy is now dominantly preferred over on-demand therapy. Pharmaceutical companies are increasing their investments in an attempt to advance prophylactic treatment and the availability of advanced and convenient delivery systems, which will lead to increased patient compliance. GlobalData, the industry analysis specialist, has released its new report, “Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Hemophilia Therapeutics market. The report identifies the key trends shaping and driving the global Hemophilia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hemophilia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number